Stiftung Institut fuer Herzinfarktforschung
Quick facts
Phase 3 pipeline
- Clopidogrel (Iscover/Plavix) · Cardiovascular
Clopidogrel irreversibly inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets. - Zodin (drug)
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Stiftung Institut fuer Herzinfarktforschung portfolio CI brief
- Stiftung Institut fuer Herzinfarktforschung pipeline updates RSS
Frequently asked questions about Stiftung Institut fuer Herzinfarktforschung
What is Stiftung Institut fuer Herzinfarktforschung's pipeline?
Stiftung Institut fuer Herzinfarktforschung has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Clopidogrel (Iscover/Plavix), Zodin (drug).
Related
- Sector hub: All tracked pharma companies